Japan· JP-1239003F1046
ピリドスチグミン臭化物
A pyridostigmine product containing ピリドスチグミン臭化物, registered in Japan by 共和薬品工業, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Pyridostigmine is registered in 16 of 19 countries.
Countries holding a registration under ATC N07AA02 (pyridostigmine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Pyridostigmine · ATC N07AA02
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pyridostigmine costs, country by country.
Normalised to the WHO defined daily dose (0.18 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pyridostigmine · price per daily dose (0.18 g)
USD · FX 28 Sept 2026
- CH Switzerland$2.06
- FR France$1.63
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ピリドスチグミン臭化物
- Manufacturer
- 共和薬品工業
- Country
- Japan (JP)
- ATC code
- N07AA02
- ATC class
- Pyridostigmine
- Defined daily dose
- 0.18 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
106 interactions on record for pyridostigmine.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pyridostigmine · interactions on record
106 records
- 2 severe
- 56 moderate
- 48 info
Most severe, free to view
- SiponimodL04AA42severe
- SiponimodL04AE03severe
- DicycloverineA03AA07moderate
- PropanthelineA03AB05moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N07AA02
Pyridostigmine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c8a488c4-2bc1-4d65-99b6-c5176385d980 GET /v1/drugs/c8a488c4-2bc1-4d65-99b6-c5176385d980?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "６０ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1239003F1046",
"category": "内用薬",
"price_yen": 14,
"generic_name": "ピリドスチグミン臭化物",
"product_name_jp": null,
"therapeutic_class": "1239",
"transitional_expiry": null
}See everything about pyridostigmine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.